Indications - Temporarily restores the viscoelasticity of the synovial fluid; - brings clinical benefits to patients in all states of arthrosis of the joints; - it is more effective in patients who actively and regularly use the joint affected by the disease; - achieves its therapeutic effect through viscosupplementation, a process through which the physiological state and rheological characteristics of the tissues of the arthritic joint are restored. It is indicated for intra-articular use by a physician only for the symptomatic treatment of pain associated with osteoarthritis of the knee. Viscosupplementation with Jonexa is indicated to relieve pain and functional limitations, allowing for more extended movement of the joint.
Dosage and method of use Inject at room temperature. Strictly adhere to aseptic techniques. The use of topical and subcutaneous anesthetics is not necessary; their use is at the discretion of the physician. Use only 18 to 20 gauge needles. Remove synovial fluid or effusion before each injection. Gently aspirate the joint. Do not use the same syringe to aspirate synovial fluid and to inject, but use the same 18-gauge to 20-gauge needle. Remove the syringe from the package by holding the syringe barrel tightly without touching the plunger rod. Be especially careful when removing the syringe tip using strictly aseptic procedures. To ensure a tight seal and to avoid spillage during administration, make sure the needle is firmly seated on the syringe by holding the Luer connector firmly. Do not tighten or exert excessive pressure when applying the needle or removing the needle guard as this could break the tip of the syringe. Inject only into the synovial space. A strictly aseptic administration technique must be used.
Features Sterile, colorless, non-pyrogenic viscoelastic liquid with neutral pH and osmolality compatible with the synovial fluid. Jonexa is a derivative of hylastan, a sodium hyaluronate (HA) gel chemically crosslinked with divinylsulfone and a liquid sodium hyaluronate. Jonexa is a mixture composed of a hylastan gel and a liquid based on HA in the gel-liquid ratio of 80:20. The sodium hyaluronate used in the preparation of Jonexa is obtained from bacterial fermentation. Hyaluronan (sodium hyaluronate) is a natural complex sugar belonging to the glycosaminoglycan family consisting of a long-chain polymer of repeated disaccharide units of sodium D-glucuronate and N-acetyl-D-glucosamine, joined by means of β glycosidic bonds -1.3 and β-1.4. The contents of each Jonexa syringe are sterile and non-pyrogenic. Jonexa is metabolized in the body in a biologically similar way to hyaluronan. Hyaluronan is one of the components of the synovial fluid and determines its viscoelastic characteristics. The mechanical (viscoelastic) properties of Jonexa are similar to those of synovial fluid and superior to those of unchanged hyaluronan-based solutions of similar concentration. Jonexa has an elasticity (storage modulus G ') at 5 Hz between 20 and 150 Pascal (Pa) and a dynamic viscosity (shear viscosity) (η) between 30 and 100 Pascal / second (Pas) measured at 1 s -1. The elasticity and viscosity of the synovial fluid of the knee in subjects aged between 18 and 27 years, measured with a technique that can be superimposed on 2.5 Hz, are respectively equal to G '= 117 Pa and G = 45 Pa. syringes preloaded with Jonexa are sterilized at the end of each production process by heat. The contents of the syringe are sterile and for single use only. It is a product.
Contraindications Do not administer to patients with known hypersensitivity (allergy) to hyaluronan (sodium hyaluronate) preparations. It must not be used in the presence of infections or severe inflammation or skin diseases or skin infections in the area where the injection is made. It should not be used if a major intra-articular effusion has occurred prior to the injection. It must not be injected into the joint in the presence of venous or lymphatic stasis in the affected limb.
Warnings Do not use concomitantly disinfectants containing quaternary ammonium salts for skin preparation as hyaluronan could precipitate in their presence. Do not inject outside of joints or into tissues or synovial capsule. Do not inject into a jar. As with all invasive joint-related procedures, it is recommended that the patient avoid any excessive motor activity following the intra-articular injection and resume full activity within a few days. Jonexa has not been tested in pregnant women or in children / adolescents under the age of 18.
Components for 1 ml Hyaluronan polymers (modified and unchanged) 10.5 ± 1 mg; sodium chloride 8.5 mg; disodium hydrogen phosphate heptahydrate 2.2 mg; sodium dihydrogen phosphate monohydrate 0.26 mg; water for injections to taste
storage Store Jonexa at a temperature between 2 and 30 ° C. Do not use if package is opened or damaged. The contents of the syringe should be used immediately after opening the package. Discard any unused hylastan SGL-80 residue. Do not resterilize.
Format 5 ml glass syringe preloaded with about 4 ml of soft-gel
National shipments with express courier: TNT, GLS
European shipments with express courier: FedEx, MBE, DHL
*For the shipment outside band B ther's an extra cost of 22€
*For the shipment outside band C ther's an extra cost of 30€
Delivery Times exclude Saturday and Holidays
For Islands and Areas of difficult Accessibility the shipments are made in 72 hours and the cost will be increased by 15€
The images of the products shown on our site are purely indicative and may differ in shape, color, text and packaging shown on them. Given the difficulty of updating all the products on our site in real time or any errors, XFarma.it, all products will be identified through SKU MINSAN (code of the Ministry of Health).
The transport of medicines sold online is carried out in compliance with the guidelines on good distribution practice according to Article 112-quater, paragraph 10. (Italy)